Home LiteratureArticle Details
PMID: 1314165 Published · ppublish English Journal Article

p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer.

The EMBO journal ·Vol. 11 ·No. 4 ·1992-04-00 ·Pages 1383-90

Unger T, Nau MM, Segal S, Minna JD

Abstract

Gal4-p53 fusion constructs demonstrate that wild type p53 is a potent transactivator in human lung cancer cells with the transactivation domain for p53 residing in amino acids 1-42. Strikingly, a variety of lung cancer derived p53 mutations occurring outside this domain disrupt this activity. Temperature sensitive conformational shifts of p53 mutant proteins to the wild type form exist and, with a temperature downshift, several mutants become transcriptionally active. Wild type p53 protein is known to form oligomers with mutant p53 and cotransfection of wild type and mutant genes shows that p53 acts in a transdominant manner that is independent of the DNA binding specificity. Transcription is either increased or decreased depending on whether the wild type is more or less abundant than the mutant form. Finally, lung cancers differ in their ability to support the transactivation related functions, providing evidence of other abnormalities of the p53 system in human cancer.

Related Genes
MeSH Terms
Amino Acid Sequence Carcinoma, Non-Small-Cell Lung Carcinoma, Small Cell Cell Line Chimera Chloramphenicol O-Acetyltransferase/genetics,metabolism Chromosome Deletion DNA-Binding Proteins Fungal Proteins/genetics,metabolism Gene Expression Regulation, Neoplastic Genes, p53 Humans Immunoblotting Luciferases/genetics,metabolism Lung Neoplasms Mutation Recombinant Fusion Proteins/metabolism Saccharomyces cerevisiae Proteins Transcription Factors/metabolism Transcription, Genetic Transfection Tumor Suppressor Protein p53/genetics,metabolism
Chemicals
DNA-Binding Proteins Fungal Proteins GAL4 protein, S cerevisiae Recombinant Fusion Proteins Saccharomyces cerevisiae Proteins Transcription Factors Tumor Suppressor Protein p53 Luciferases Chloramphenicol O-Acetyltransferase
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Unger T
National Cancer Institute, NCI-Navy Medical Oncology Branch, Bethesda, MD.
Nau M M
Segal S
Minna J D
References (35)
35 references, click to expand
  1. The MCK enhancer contains a p53 responsive element.
    Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4570-1 PMID: 1647009
  2. Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells.
    EMBO J. 1985 May;4(5):1251-5 PMID: 4006916
  3. Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product.
    Cell. 1991 Feb 8;64(3):521-32 PMID: 1825028
  4. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
    Oncogene. 1990 Oct;5(10):1603-10 PMID: 1979160
  5. The p53 tumour suppressor gene.
    Nature. 1991 Jun 6;351(6326):453-6 PMID: 2046748
  6. Structural aspects of the p53 protein in relation to gene evolution.
    Oncogene. 1990 Jul;5(7):945-52 PMID: 2142762
  7. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.
    Cell. 1990 Aug 24;62(4):671-80 PMID: 2143698
  8. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.
    Science. 1990 Aug 31;249(4972):1049-51 PMID: 2144364
  9. An amino-terminal c-myc domain required for neoplastic transformation activates transcription.
    Mol Cell Biol. 1990 Nov;10(11):5914-20 PMID: 2233723
  10. Temperature-dependent switching between "wild-type" and "mutant" forms of p53-Val135.
    J Mol Biol. 1990 Dec 5;216(3):481-4 PMID: 2258922
  11. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression.
    Eur J Biochem. 1986 Sep 15;159(3):529-34 PMID: 2428616
  12. The p53 proto-oncogene can act as a suppressor of transformation.
    Cell. 1989 Jun 30;57(7):1083-93 PMID: 2525423
  13. Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins.
    Science. 1989 Jul 28;245(4916):371-8 PMID: 2667136
  14. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.
    Proc Natl Acad Sci U S A. 1987 Nov;84(21):7413-7 PMID: 2823261
  15. Evidence of DNA: protein interactions that mediate HSV-1 immediate early gene activation by VP16.
    Genes Dev. 1988 Jun;2(6):730-42 PMID: 2843426
  16. Meth A fibrosarcoma cells express two transforming mutant p53 species.
    Oncogene. 1988 Sep;3(3):313-21 PMID: 3060794
  17. DNA-bound Fos proteins activate transcription in yeast.
    Cell. 1988 Jan 29;52(2):179-84 PMID: 3124961
  18. The relationship between micrometastases in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis.
    Am J Clin Pathol. 1988 Jul;90(1):1-6 PMID: 3389336
  19. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.
    Cancer Res. 1986 Feb;46(2):798-806 PMID: 3940644
  20. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
    Nature. 1970 Aug 15;227(5259):680-5 PMID: 5432063
  21. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.
    Mol Cell Biol. 1982 Sep;2(9):1044-51 PMID: 6960240
  22. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication.
    Cell. 1991 Jun 14;65(6):1083-91 PMID: 1646078
  23. p53 mutations in human cancers.
    Science. 1991 Jul 5;253(5015):49-53 PMID: 1905840
  24. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.
    Cell. 1991 May 31;65(5):765-74 PMID: 2040013
  25. Identification of p53 as a sequence-specific DNA-binding protein.
    Science. 1991 Jun 21;252(5013):1708-11 PMID: 2047879
  26. Presence of a potent transcription activating sequence in the p53 protein.
    Science. 1990 Aug 31;249(4972):1046-9 PMID: 2144363
  27. Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer.
    J Clin Invest. 1990 Jul;86(1):363-9 PMID: 2164047
  28. A potential transcriptional activation element in the p53 protein.
    Oncogene. 1990 Dec;5(12):1829-32 PMID: 2284102
  29. Transcription activation by the adenovirus E1a protein.
    Nature. 1989 Mar 2;338(6210):39-44 PMID: 2521923
  30. p53: a frequent target for genetic abnormalities in lung cancer.
    Science. 1989 Oct 27;246(4929):491-4 PMID: 2554494
  31. Gastrin-releasing peptide gene-associated peptides are expressed in normal human fetal lung and small cell lung cancer: a novel peptide family found in man.
    J Clin Endocrinol Metab. 1988 Sep;67(3):576-83 PMID: 2842362
  32. GAL4-VP16 is an unusually potent transcriptional activator.
    Nature. 1988 Oct 6;335(6190):563-4 PMID: 3047590
  33. Immortalization of rat embryo fibroblasts by the cellular p53 oncogene.
    Oncogene. 1988 May;2(5):445-52 PMID: 3287278
  34. Firefly luciferase gene: structure and expression in mammalian cells.
    Mol Cell Biol. 1987 Feb;7(2):725-37 PMID: 3821727
  35. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.
    EMBO J. 1990 May;9(5):1595-602 PMID: 1691710
Article Info
Journal
The EMBO journal
Abbr.
EMBO J
ISSN
0261-4189
Published
1992-04-00
Pages
1383-90
Language
English
Region
England
NLM ID
8208664
PMCID
PMC556587
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com